Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06149793 · ClinicalTrials.gov registry record · Phase 2

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

A Phase 2 study of Cystic Fibrosis and Cystic Fibrosis-related Diabetes, sponsored by University of Minnesota.

Active
Registry status
Phase 2
Development phase
8
Enrollment target
1
Study location

NCT06149793: Active Phase 2 study of Cystic Fibrosis and Cystic Fibrosis-related Diabetes, sponsored by University of Minnesota.

NCT06149793 is a Phase 2 study of Cystic Fibrosis and Cystic Fibrosis-related Diabetes that is active but no longer recruiting, run by University of Minnesota. The registered enrollment target is 8 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06149793, a Phase 2 study of Cystic Fibrosis and Cystic Fibrosis-related Diabetes, is active but no longer recruiting, sponsored by University of Minnesota.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.

Primary Outcome

The primary outcomes are related to feasibility, including safety and treatment tolerability. Safety will be evaluated as the proportion (in %) of participants who experience a serious adverse event during the study. Tolerability will be evaluated as the proportion (in %) of participants who discontinue their assigned treatment due to side effects.

Conditions Studied

Cystic Fibrosis Cystic Fibrosis-related Diabetes

Interventions

  • DRUG Empagliflozin
  • OTHER Placebo Control

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-01-08
Est. Completion 2026-12-31
Phase Phase 2
University of Minnesota

966 total trials

What the registry record for NCT06149793 still lists

NCT06149793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.

NCT06149793 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06149793 about?

NCT06149793 is a clinical study titled "SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes". This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.

What is the current status of trial NCT06149793?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2024-01-08. Estimated completion is 2026-12-31.

What conditions does trial NCT06149793 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes.

What interventions are being tested in trial NCT06149793?

The interventions under investigation include: Empagliflozin (DRUG), Placebo Control (OTHER).

Who is sponsoring clinical trial NCT06149793?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06149793 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06149793's enrollment target sits among peer trials

8 165th of 169 higher than 3 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06149793, the US trial registry maintained by the National Library of Medicine. NCT06149793 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.